{"DataElement":{"publicId":"5709753","version":"1","preferredName":"Prior Biological Therapy Administered Type","preferredDefinition":"The type of Biphosphonate therapy was used before the current study.","longName":"PRIO_BIPHOS_THERP_TYP","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2190855","version":"1","preferredName":"Prior Biological Therapy Administered","preferredDefinition":"information related to biological therapy administered previously.","longName":"PRIOR_BIOTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206751","version":"1","preferredName":"Prior Biological Therapy","preferredDefinition":"Earlier in time or order.:Treatment of disease by the administration of substances which produce a biological reaction in the organism. It includes the use of sera, antitoxins, vaccines, cells, tissues, and organs. (From Dorland, 28th ed)","longName":"C25629:C0005527","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Biological Therapy","conceptCode":"C0005527","definition":"Treatment of disease by the administration of substances which produce a biological reaction in the organism. It includes the use of sera, antitoxins, vaccines, cells, tissues, and organs. (From Dorland, 28th ed)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0309-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7D7251C-548A-5E2C-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-02","endDate":null,"createdBy":"PWEST","dateCreated":"2004-11-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5709610","version":"1","preferredName":"Biphosphonate Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"5709610v1.0","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Fosamax","valueDescription":"Alendronate Sodium","ValueMeaning":{"publicId":"2576907","version":"1","preferredName":"Alendronate Sodium","longName":"2576907","preferredDefinition":"A bisphosphonate with increased antiresorption activity (100x-1000x that of etidronate).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alendronate Sodium","conceptCode":"C973","definition":"The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1CD9-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Actonel","valueDescription":"Risedronate Sodium","ValueMeaning":{"publicId":"5709611","version":"1","preferredName":"Risedronate Sodium","longName":"5709611","preferredDefinition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risedronate Sodium","conceptCode":"C1528","definition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1CE4-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1CFD-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Aredia","valueDescription":"Pamidronate Disodium","ValueMeaning":{"publicId":"2576642","version":"1","preferredName":"Pamidronate Disodium","longName":"2576642","preferredDefinition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamidronate Disodium","conceptCode":"C1345","definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1D11-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Boniva","valueDescription":"Ibandronate Sodium","ValueMeaning":{"publicId":"2597181","version":"1","preferredName":"Ibandronate Sodium","longName":"2597181","preferredDefinition":"The sodium salt form of ibandronate, a synthetic nitrogen-containing bisphosphonate.  Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibandronate Sodium","conceptCode":"C1670","definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C181-8505-54D4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1D25-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1D2F-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1D39-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"},{"value":"Zometa","valueDescription":"Zoledronic Acid","ValueMeaning":{"publicId":"5709612","version":"1","preferredName":"Zoledronic Acid","longName":"5709612","preferredDefinition":"A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1D43-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Zometa as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AA0A7DB-1D5B-7C8E-E053-F662850A3136","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ONEDATA","dateModified":"2017-03-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2749690","version":"1","preferredName":"Therapeutic Procedure Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D35F706-1F30-4E8C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-14","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-05-14","modifiedBy":"ONEDATA","dateModified":"2008-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1CB9-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"MAESKEB","dateModified":"2017-10-11","changeDescription":"3/13/2017 created for DCP SVAR","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280818","version":"1","longName":"UWI2014-03-01","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior Biphosphonate Therapy","type":"Preferred Question Text","description":"Prior Biphosphonate Therapy","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA09834-B066-0EB3-E053-F662850AFD4B","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"LISU","dateModified":"2020-06-07","changeDescription":"3/13/2017 created for DCP SVAR, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}